Echo Therapeutics (ECTE) and Tonix Pharmaceuticals (TNXP) Head-To-Head Review

Echo Therapeutics (OTCMKTS: ECTE) and Tonix Pharmaceuticals (NASDAQ:TNXP) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, profitability, analyst recommendations, valuation, institutional ownership, dividends and risk.

Insider & Institutional Ownership

17.5% of Tonix Pharmaceuticals shares are held by institutional investors. 7.0% of Echo Therapeutics shares are held by company insiders. Comparatively, 4.0% of Tonix Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Valuation and Earnings

This table compares Echo Therapeutics and Tonix Pharmaceuticals’ revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Echo Therapeutics $60,000.00 2.06 -$22.19 million ($1.28) -0.01
Tonix Pharmaceuticals N/A N/A -$38.84 million ($4.77) -0.75

Echo Therapeutics has higher revenue and earnings than Tonix Pharmaceuticals. Tonix Pharmaceuticals is trading at a lower price-to-earnings ratio than Echo Therapeutics, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

Echo Therapeutics has a beta of 1.81, indicating that its stock price is 81% more volatile than the S&P 500. Comparatively, Tonix Pharmaceuticals has a beta of 2.92, indicating that its stock price is 192% more volatile than the S&P 500.

Profitability

This table compares Echo Therapeutics and Tonix Pharmaceuticals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Echo Therapeutics N/A N/A N/A
Tonix Pharmaceuticals N/A -78.25% -73.14%

Analyst Recommendations

This is a summary of recent ratings and recommmendations for Echo Therapeutics and Tonix Pharmaceuticals, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Echo Therapeutics 0 0 0 0 N/A
Tonix Pharmaceuticals 0 1 4 0 2.80

Tonix Pharmaceuticals has a consensus price target of $8.33, indicating a potential upside of 131.48%. Given Tonix Pharmaceuticals’ higher probable upside, analysts clearly believe Tonix Pharmaceuticals is more favorable than Echo Therapeutics.

Summary

Echo Therapeutics beats Tonix Pharmaceuticals on 6 of the 10 factors compared between the two stocks.

About Echo Therapeutics

Echo Therapeutics, Inc. is a medical device company. The Company is engaged in developing a non-invasive, wireless continuous glucose monitoring (CGM) system with use in the wearable-health consumer market, diabetes outpatient market and in the hospital setting. The Company operates through the development of transdermal skin permeation and diagnostic medical devices segment. The Company has also developed its needle-free skin preparation device as a platform technology that allows for enhanced skin permeation enabling extraction of analytes, such as glucose, enhanced delivery of topical pharmaceuticals and other applications. The CGM System includes a skin preparation device, transdermal glucose sensor, battery and wireless transmitter. The Company has conducted several human feasibility clinical studies with its CGM System in healthy subjects, diabetics and critically ill patients, as well as a clinical study at several hospitals in the United States.

About Tonix Pharmaceuticals

Tonix Pharmaceuticals Holding Corp., a clinical-stage pharmaceutical company, engages in developing pharmaceutical products for central nervous system disorders. The company’s lead program focuses on post-traumatic stress disorder (PTSD) that is characterized by chronic disability, inadequate treatment options, high utilization of healthcare services, and economic burden. Its lead product candidate includes TNX-102 SL, a cyclobenzaprine HCl sublingual tablet, which is in Phase III clinical stage for the treatment of PTSD; and Phase III clinical stage for the treatment of military-related PTSD. The company’s product candidates also include TNX-601, an oral formulation of tianeptine oxalate for PTSD and cognitive dysfunction associated with steroid use; TNX-801, a smallpox-preventing vaccine based on a live synthetic version of horsepox virus; TNX-301, a fixed-dose combination drug product for alcohol use disorders; and TNX-701 for radiation injuries. Tonix Pharmaceuticals Holding Corp. was founded in 2007 and is based in New York, New York.

Receive News & Ratings for Echo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Echo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply